Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: trofala who wrote (1818)	10/23/1998 12:15:00 AM
From: Sigmund	Read Replies (1) \| Respond to of 1894

<<<< for use with ThinPrep(R)liquid-based preparations marketed by Cytyc Corp.<<<< note CYTC earnings report issued after market close today. IMO ACMI will be an acquisition target as soon as the Micro Division is sold. It will be a relatively clean cytology company with additional potential in Savant. Their burn rate will now be lower. Who are the potential buyers? NPTH CYTC ACYT Can you put ACMI and its ThinPrep approval for TracCell together with AutoPap and get something that works and is legal? Can you put CYTC together with TracCell and get primary screening? If you can do the above with CYTC can you extend it to other similar products such as the product developed by ACYT? For sure you get semi-automated screening. Perhaps you can get automated screening with additional FDA review. Is it cost effective for either NPTH, CYTC or ACYT to build on the ACMI product rather than build on their own from what they have? These are some of the questions that need to be answered. Any thoughts on this?